Daniel Caruso, MD
Endocrinology, Diabetes & Metabolism · Reno, NVNPI 1558378778
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.5% of the total across 429 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations.
Across 429 payments — averaging $27.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Insulet Corporation$1K
- Sanofi-aventis U.S. LLC$1K
- Medtronic$1K
- Mannkind Corporation$897
- AstraZeneca$747
- plus $5K from 30 others
Across 14 payments — averaging $595.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dexcom, Inc.$8K
What the payments were for
- Speaking & faculty fees$7556%
- Food & beverage$10,93393%
- Education$701%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 80 | $1,508 |
| Insulet Corporation | 50 | $1,074 |
| Sanofi-aventis U.S. LLC | 20 | $1,067 |
| Medtronic(2 entities) | 46 | $1,041 |
| Mannkind Corporation | 42 | $897 |
| AstraZeneca(2 entities) | 26 | $747 |
| Amgen(2 entities) | 18 | $549 |
| Abbott | 27 | $517 |
| Tandem Diabetes Care, Inc. | 11 | $455 |
| Corcept Therapeutics | 9 | $426 |
| Boehringer Ingelheim | 14 | $419 |
| AbbVie | 12 | $410 |
| Radius Health, Inc. | 9 | $359 |
| Ascendis Pharma Endocrinology Inc | 5 | $222 |
| Zealand Pharma US, Inc. | 7 | $187 |
| Sanofi | 1 | $185 |
| Dexcom, Inc. | 4 | $174 |
| Lightforce Orthodontics, Inc. | 4 | $166 |
| Kyowa Kirin, Inc. | 6 | $149 |
| Novo Nordisk | 4 | $125 |
| Companion Medical, Inc. | 2 | $125 |
| Amarin Pharma, Inc. | 2 | $102 |
| Johnson & Johnson(2 entities) | 2 | $97 |
| Shire North American Group Inc | 1 | $95 |
| Ascensia Diabetes Care US Inc. | 2 | $94 |
| Xeris Pharmaceuticals, Inc. | 4 | $85 |
| Lexicon Pharmaceuticals, Inc. | 1 | $83 |
| Valeritas, Inc. | 1 | $83 |
| Bayer | 4 | $82 |
| Merck | 5 | $77 |
| Recordati_rare_diseases_inc. | 3 | $64 |
| Almatica Pharma LLC | 2 | $46 |
| IBSA Pharma Inc. | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Boehringer Ingelheim International GmbH | 1 | $22 |
| Halozyme Inc | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$400
- TEPEZZA$239
- Omnipod$235
- TZIELD$223
- AFREZZA$222
- Korlym$220
- TOUJEO$185
- DEXCOM G7 GSS (161)$125
- t-slim insulin pump$124
- FREESTYLE LIBRE 3$124
- Tymlos$124
- Minimed 670G System$123
- t:slim X2 Insulin Pump with Control-IQ$117
- MOUNJARO$108
- InPen$104
How this compares
$11,817 in reported general payments places this provider in the 75th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
See all endocrinology, diabetes & metabolism providers in Nevada →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 124 | $184,685 |
| MounjaroTirzepatide | 121 | $154,503 |
| TrulicityDulaglutide | 70 | $114,982 |
| JardianceEmpagliflozin | 82 | $92,975 |
| FarxigaDapagliflozin Propanediol | 48 | $55,603 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $53,376 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 47 | $32,847 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 22 | $32,713 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 25 | $31,584 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 23 | $29,558 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $28,136 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 28 | $25,469 |
| RybelsusSemaglutide | 18 | $25,149 |
| FiaspInsulin Aspart (Niacinamide) | 22 | $22,594 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $22,042 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,508 | $278,023224 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Fiasp, Novolog | $125 | $270,928206 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $419 | $122,533105 claims |
| AstraZenecaFarxiga | $747 | $55,60348 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,067 | $31,58425 claims |
| AbbVieSynthroid | $410 | $5,23146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
Other endocrinology, diabetes & metabolism in Reno
- Nitesh KuhadiyaReno$595K
- Lisa AbbottReno$130K
- Michael Raymund GonzalesReno$90K
- Claude LardinoisReno$65K
- Sarah MoatsReno$23K
- Robert FredericksReno$10K
- Polina ZykovaReno$7K
- David HowardReno$2K
- James AtchesonReno$2K
- Fadi HendeeReno$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.